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Myopathies are chronic degenerative pathologies that induce the deterioration of the structure and function of skeletal muscle.
So far a de)nitive therapy has not yet been developed and the main aim of myopathy treatment is to slow the progression of
the disease. Current nonpharmacological therapies include rehabilitation, ventilator assistance, and nutritional supplements, all of
which aim to delay the onset of the disease and relieve its symptoms. Besides an adequate diet, nutritional supplements could play
an important role in the treatment of myopathic patients. Here we review the most recent in vitro and in vivo studies investigating
the role supplementation with creatine, L-carnitine, and 휔3 PUFAs plays in myopathy treatment. Our results suggest that these
dietary supplements could have bene)cial e+ects; nevertheless continued studies are required before they could be recommended
as a routine treatment in muscle diseases.
1. Introduction
(e role of many foods/nutrients in maintaining good health
and prolonging human lifespan has been clearly demon-
strated over the past three decades. Particularly important
are not only plant foodstu+s (i.e., fruits, vegetables, and
legumes), but also animal foods (i.e., )sh) and lipids (,axseed
and olive oils), that have been shown to have protective
e+ects against several chronic pathologies such as age-related
diseases, including cardiovascular [1], neurodegenerative [2],
and in,ammatory diseases [3], diabetes [4], and myopathies.
Myopathies can be classi)ed as either hereditary or acquired.
Congenital myopathies are a group of inherited neuromuscu-
lar disorders whose main pathological features are distinctive
and speci)c morphologic abnormalities in skeletal muscle.
In contrast, di+erently acquired myopathies are caused by
muscle fatigue, electrolyte imbalance, and dehydration or
are induced by immune disorders that cause in,ammation
and pain [5]. In these pathologies the skeletal muscle is the
fundamental target.
(e deterioration of skeletal muscle structure and func-
tion leads to clinically relevant complaints, including pro-
gressive strength loss, fatigue, myalgias, and cramps. Impor-
tant progress has been made in the comprehension of
??????????????????????????????
?????????????????????????????
????????????? ??????????????????????????
?????????????????????????????????????
2 BioMed Research International
HO
NH2
NH
O
N
Figure 1: Chemical structure of creatine.
the molecular mechanisms underlying muscle myopathies.
However, the treatment of muscle diseases is mainly
symptom-oriented and includes physical therapy, physical
exercise, orthopaedic corrections, arti)cial ventilation in
cases of respiratory insu3ciency, and pharmacologic inter-
ventions (i.e., corticosteroids). Considering the lack of ther-
apies for myopathies, the idea that nutritional supplements
might have bene)cial e+ects in myopathy treatment is expe-
riencing renewed interest. Conclusions about how bene)cial
nutritional supplements are for myopathy treatment are
complicated by a lack of unequivocal results and ,aws in the
choice of supplements.
On the basis of their physiological roles in muscle
biochemistry and bioenergetics, the nutrients creatine, L-
carnitine, and 휔3 polyunsaturated fatty acids (휔3 PUFAs)
have been the focus of research aimed at verifying their safety
and e3cacy in treatment of a number ofmuscle diseases. Our
aim here is to review the results of the most recent in vitro
and in vivo research on the supplementation of creatine, L-
carnitine, and 휔3 PUFAs.
2. Creatine
2.1. ,e Nutritional Biochemistry of Creatine. Creatine (N-
aminoiminomethyl-N-methylglycine, Figure 1) is an endoge-
nous guanidine compound, which is synthesized by the
kidneys, pancreas, and liver, starting from three amino acids:
(1) methionine, which provides the methyl group through
a transmethylation reaction, (2) glycine, which provides
the acetic group and the nitrogen atom, and (3) arginine,
which provides the amide group. Once produced, creatine
is released into the bloodstream and then mainly captured
by the cardiac and skeletal muscle and brain. To carry out
its physiological role, creatine is converted to phosphocrea-
tine by creatine kinase. (e donor of the phosphate group
is adenosine triphosphate (ATP), which is converted into
adenosine diphosphate (ADP). Phosphocreatineis ahigh-
energy reserve, availablefor theconversionof ADP to ATP,
that is, essential during periods of high energy demand
such as intense physical activity. Creatine kinase catalyzes
the reversible transfer of the N-phosphoryl group from
phosphorylcreatine to ADP to regenerate ATP. In this way
creatine levels are restored [6]. In a 70 kg man, the total body
creatine content is about 120 g, with a turnover of about 2 g/d,
corresponding to 1.6%of total body creatine.On average, 50%
of an individual’s daily requirement of creatine is ingested
from foods (approximately 1 g/d), while the remaining 50%
is synthesized endogenously. Exogenous dietary sources of
creatine include meat and )sh (the concentration of creatine
ranges between 4 and 5 g/kg of meat and 4 and 10 gr/kg of
)sh), and other animal products.
To date, the e+ects of creatine supplementation onmuscle
growth and muscle performance have been documented in
more than 400 publications. Scienti)c evidence suggests that
creatine supplementation (with a considered safe loading
dose of 4 g of creatine monohydrate, 4 times per day), is an
e+ective strategy to increase muscle creatine content by up to
10–40%, in less than aweek [7].(is supplementation induces
the increase of anaerobic performance, training volume, and
capacity of humanmuscle to performworkduring alternating
intensity contraction [8].
Moreover, creatine also plays a pivotal role in brain energy
homeostasis. It has been shown that in some psychiatric
disorders, such as depression, the levels of creatine are low [9].
(erefore, recent studies have investigated the e+ect of cre-
atine monohydrate supplementation in psychiatric patients
su+ering from posttraumatic stress disorders and depression.
Creatine supplementation seems to also show neuropro-
tective e+ects in some neurodegenerative pathologies such
as Alzheimer’s and Parkinson’s diseases. Recent evidence
suggests that creatine could play important roles in the
dysfunction of mitochondrial metabolism, which is rec-
ognized as a central causal factor in the pathogenesis of
neurodegenerative disorders [10]. In a phase-II clinical trial,
creatine monohydrate showed a delay in the progression
of Parkinson’s disease by 50%, compared to controls that
received placebo. (en, in a subsequent followup study
carried out 18 months later, creatine continued to show
e3cacy as a neuroprotective agent. (e authors concluded
that for its safety, tolerability, activity, and cost, creatine has
many advantages in comparison with other drugs or food
supplements potentially useful for Parkinson’s disease [11, 12].
2.2. ,e E-ects of Creatine Supplementation on Muscle Dis-
eases. Creatine monohydrate supplementation, at dose of
0.3 g/kg/d for six days or 0.04 g/kg/d for 30 days [13],
induces an increase in total creatine and phosphocreatine
concentrations in skeletal muscle [13, 14], the magnitude of
accumulation being inversely related to available endogenous
stores [14]. It is accepted that the dosing regimen that
signi)cantly increase the intracellular phosphocreatine is a
loading phase of approximately 20 g/d for 5–7 days followed
by a maintenance phase of 5 g/d for several weeks [15, 16].
In healthy strength trained humans [17–19], creatine
monohydrate supplementation has been shown to improve
performance [14, 20], force output [20–22], and muscle free
mass [13, 14, 23, 24]. In particular, creatine is an ergogenic
aid (i.e., a temporal energy bu+er) when supplementation
is associated with high intensity exercise and the e+ect is
more pronounced in untrained versus trained and in elderly
versus young individuals [25], whereas similar changes in
muscle performance have been found in males and females
[14, 20]. (e accepted mechanism explaining the positive
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e+ect of creatine supplementation on performance consists
of the temporal energy bu+ering due to the enhancement of
the resting high energy phosphate levels (total creatine, phos-
phocreatine, creatine, and ATP), leading to a better match
between ATP supply and the muscle )bers demands during
physical exercise [26]. (is change allows users to improve
performance through increased total training volume. Cre-
atine monohydrate supplementation is also well known for
being responsible of a hypertrophic response determining an
increased fat-free mass of about one kilogram [13, 14, 23, 24].
(e hypertrophic potential following creatine administration
has been mostly linked to ,uid retention in myo)bers due to
swelling-induced osmotic potential of high intracellular crea-
tine [24, 27]. An increased expression of myosin heavy chain
isoforms [28] and myogenic regulatory factors [29, 30] and
an improved mitotic activity of satellite cells have also been
considered as key determinants of the net protein deposition
following supplementation. (e overall e+ects of creatine
monohydrate supplementation on muscle structure have
prompted researchers to investigate its e3cacy in treating
exercise-induced muscle injuries [26]. So far, contradictory
results have been reported. While some studies on animal
models and humans show that creatine supplementation does
not decrease muscle damage or enhance recovery a5er high
intensity eccentric contractions [31, 32], others have shown
contradicting results as a greater isokinetic and isometric
strength and a quicker amelioration of plasma creatine
kinase (CK) levels during recovery were observed following
creatine supplementation from an exercise-induced muscle
damage [33]. Given the con,icting results from experiments
investigating the e3cacy of creatine treatment on skeletal
muscle damage and recovery from eccentric-exercise damage
we, and others [26], encourage further research to understand
what, if any, role creatine treatment can play. Importantly, an
anti-in,ammatory e+ect of creatine has been observed when
its supplementationwas used in runners (with previous expe-
rience in runningmarathons) before a long distance race [34].
(is protective e+ect has been con)rmed in double blind
trials when creatine supplementation (20 g d-1) was adminis-
tered before high intensity endurance competitions [35, 36].
It is possible that the bene)ts of creatine supplementation
in preventing muscle damage may relate to its antioxidant
potential in endurance settings [26]. However, few studies
have been published on the relationship between supplemen-
tation and oxidative stress, and controversial and inconclu-
sive results have been obtained on indicators of oxidative
damage [37–39]. Accordingly, creatine supplementation has
been associated with either no change of lipid peroxidation,
resistance of low density lipoprotein to oxidative stress or
plasma concentrations of nonenzymatic antioxidants [39],
increased free radical generation [37], and reduced oxidative
stress [38]. In particular, Rahimi in [38] found a signi)cant
increase in athletic performance combined with attenua-
tion of plasma malondialdehyde and urinary 8-hydroxy-2-
deoxyguanosine levels inmenwho underwent 7 days creatine
monohydrate supplementation (20 g/d) before a resistance
exercise protocol.(ese results suggested a reduced training-
induced oxidative stress and lipid peroxidation associated
with supplementation [38]. However, no change [39] or
an increase [37] in lipid peroxidation, resistance of low den-
sity lipoprotein to oxidative stress and plasma concentrations
of nonenzymatic antioxidants has also been reported in adult
males performing exhaustive incremental exercise trials com-
bined with creatine supplementation. Taken together, these
observations show that creatine supplementation may help
in maintaining muscle integrity a5er intense and prolonged
exercise, yet the mechanisms underlying the protective e+ect
are only partially known.
(e e+ects of creatine supplementation on muscle per-
formance and protein metabolism and, possibly, muscle
integrity may represent a rationale for its potential use to
prevent or treat muscle disorders. Creatine monohydrate
supplementation may bene)t muscle disorders in a nonspe-
ci)c fashion [40] by enhancing muscle strength and mass,
reducing intracellular calcium accumulation and apoptosis
[41], preventing oxidative stress, and attenuating cell death
[42]. In fact, in myopathy, pathophysiological events lead to
)ber necrosis, apoptosis, autophagy elevation in reactive oxy-
gen species, mitochondrial dysfunction, increases in protein
catabolism and degradation, and rise in intracellular calcium
content [43], and all these elements may represent sites of
attack for creatine. Furthermore a reduced creatine disposal
may characterize neuromuscular disorders [44–49], due to
the lower creatine transporter content or the impairment
of energy charging capacity of the cells. (is condition of
relative creatine de)ciency may boost the need for dietary
supplementation. (e e3cacy of creatine supplementation
in muscle diseases has been observed in animal models
and humans. For instance, in mdx mice (a model of dys-
trophinopathy), an improved calcium handling resulting in
lower intracellular calcium concentrations and enhanced cell
survival have been shown in cultured cells [50]. In the same
animal model an improvement of mitochondrial respiration
and muscle function has been also observed [51]. In 1997, a
prospective randomized study reporting the positive e+ects
of creatine monohydrate supplementation in a neuromuscu-
lar disease (i.e. mitochondrial myopathy) was )rst published
[52]. In this study creatine monohydrate was administered
in 7 mitochondrial cytopathy patients using a randomized
crossover design with the following scheme: 5 g for the )rst
14 days followed by 2 g of oral creatine monohydrate for the
subsequent 7 days. Measurements included activities of daily
living, isometric handgrip strength, basal and postexercise
lactate, evoked and voluntary contraction strength of the
dorsi,exors, and aerobic capacity at cycle ergometry. Cre-
atine treatment resulted in signi)cantly increased handgrip
strength, with no changes in the other measured variables
[52]. In 1999, Tarnopolsky and Martin [53] found an increase
in high intensity power output following creatine mono-
hydrate supplementation for 10 days (10 g daily for 5 days
followed by 5 g daily for 5 days) in a heterogeneous group
of people with neuromuscular disorders enrolled in two
studies (Study 1, 푛 = 81 open study; and Study 2, 푛 = 21
single-blinded study). In the open trial, which aimed to test
the clinical e3cacy of creatine supplementation in a large
cohort of patients, myopathies included muscle dystrophies
(푛 = 15), mitochondrial cytopathies (푛 = 17), in,ammatory
myopathies (푛 = 14), and peripheral neuropathy disorders
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(푛 = 18), whereas the single-blinded study was conducted
only on 21 heterogeneous patients (푛 = 16, miscellaneous
myopathies, 푛 = 6muscle dystrophies, 푛 = 1 peripheral neu-
ropathy disorder, and 푛 = 1 in,ammatory myopathy [53].
Despite the results from [53] being based on a limited
number of patients, the acquired knowledge has encouraged
further research aimed at testing the e+ects of creatine
supplementation in several conditions including sarcope-
nia of ageing [54, 55], dystrophies [56, 57], mitochondrial
myopathies [58, 59], COPD [60–62], and chronic heart failure
(where phosphocreatine/ATP ratio is a stronger prognostic
factor than the degree of impairment [63]). To date, the results
across all these studies remain inconclusive about a bene)cial
e+ect of creatine supplementation.
Meta-analyses of the growing literature base [40, 64, 65],
highlighting the statistical under power of the majority of
the studies, reveal that the e3cacy for long- and short-term
supplementation with creatine monohydrate is only seen in
selected muscular dystrophies (i.e., dystrophinopathies and
myotonic dystrophy type 2 and in,ammatory myopathies,
such as dermatomyositis and polymyositis) and in terms
of increased muscle strength even under anti-in,ammatory
therapies (corticosteroids). Critical analysis of the literature
shows we cannot draw safe conclusions in other myopathic
conditions, partly due to methodological biases in setting up
clinical trials and small sample sizes leading to lower power
[43]. Importantly, in all analyzed studies across all tested
myopathic conditions, creatine appeared well tolerated, apart
from treatment of glycogenosis type V (McArdle disease).
In this case treatment by creatine supplementation at high
dose rates resulted in impaired activities of daily living and
increased muscle pain (cramping) [43].
Our review of creatine supplementation has highlighted
three important points. First, creatine monohydrate supple-
mentation in healthy and diseased humans can have impor-
tant bene)cial e+ects. Second, conclusions from the study
of creatine supplementation in several myopathic conditions
are deeply hampered by methodological problems including
di3culties in statistical power due to rarity of diseases.
(ird, there are virtually no observed negative e+ects of
creatine supplementation compared to currently available
chemotherapeutic interventions. Together, these three points
strongly justify ongoing e+orts in establishing basic research,
randomized clinical trials, or other experimental designs on
testing the bene)ts of creatine supplementation.
3. L-Carnitine
3.1.,e Nutritional Biochemistry of L-Carnitine. L-Carnitine
(3-hydroxy-4-N-trimethylaminobutyrate, Figure 2), the bio-
active form of carnitine, is an endogenous branched
nonessential amino acid derivative. L-carnitine is synthesized
in kidney, liver, and testes, starting from L-lysine and L-
methionine, having ascorbic acid, ferrous iron, pyroxidine,
and niacin as cofactors. L-carnitine can also be consumed
with diet, especially with foods of animal origin. Omnivores
have a dietary intake of carnitine from 20 and 300mg/d
mostly from red meat (50–150mg/100 g), )sh, and dairy
OH O
O−
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Figure 2: Chemical structure of L-carnitine.
products (up to 10mg/100 g) consumption, whereas veg-
etarians have a dietary intake of about 1–3mg/d. Dietary
carnitine is absorbed in the small intestine and enters the
bloodstream [66]. Inside the cells, carnitine is involved
in lipid metabolism since it allows the transport of fatty
acids with more than 14 carbon atoms from the cyto-
plasm to mitochondria where they undergo 훽-oxidation
[63, 67]. (e transition takes place through three steps. (e
)rst step is catalysed by carnitine palmitoyl transferase 1
(CPT1) and the transmembrane transport is facilitated by
acylcarnitine transferase. Within the mitochondrion, free
carnitine is regenerated by the action of carnitine palmitoyl
transferase 2 (CPT2) and the released fatty acyl-CoAs enter
the 훽-oxidation pathway. Taking into account that free
CoA is involved in the pyruvate dehydrogenase reaction
and in the process of 훽-oxidation, carnitine contributes
to the coordinated integration of fat and carbohydrate
metabolism.When glucose oxidation increases, acetyl groups
can be translocated from acyl-CoA within the mitochondrial
matrix to the cytoplasm. (e accumulation of cytosolic ace-
tylcarnitine may result in a limitation of CPT-1 activity
because of the decrease in availability of free carnitine [26].
Moreover, fatty acid oxidation could occur, considering that
skeletal muscle predominantly expresses an isoform of CPT-
1 with low a3nity for L-carnitine [68]. (us, the regulation
of free fatty acids 훽-oxidation occurs through the regulation
of their mitochondrial content due to leakage of acyl and
acetyl moieties leading to a modi)cation of the ratio between
esteri)ed carnitine and free carnitine.
Considering its fundamental role in lipid metabolism, L-
carnitine is a drug approved by the Food and Drug Admin-
istration to treat primary and selected secondary carnitine-
de)ciency syndromes [69] and is widely used as food sup-
plement for its potential positive e+ect on health [70] even if
the results across available studies remain inconclusive about
a real bene)cial e+ect to treat chronic complaints as type 2
diabetes [71] andAlzheimer’s neurodegenerative disease [72].
Importantly, lines of evidence suggest positive e+ects of
carnitine supplementation in cardiovascular diseases. A
recent meta-analysis revealed that carnitine administration
leads to 27% reduction in all-cause mortality, 65% reduction
in ventricular arrhythmias, and 40% reduction in anginal
symptoms in patients experiencing an acute myocardial
infarction. (erefore L-carnitine and propionyl-L-carnitine
can be used along with conventional treatment in presence of
stable angina, thus contributing to secondary prevention of
cardiovascular diseases [73]. Interestingly promising results
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have been also obtained in presence of intermittent claudica-
tion, themost frequent symptomofmildmoderate peripheral
vascular disease, as propionyl-L-carnitine supplementation
can help reducing symptoms and is associated with signi)-
cant amelioration of functional impairment [74].
3.2. ,e E-ects of L-Carnitine Supplementation on Muscle
Diseases. (e skeletal muscle is the most relevant depository
of carnitine, and its availability is critical for the physi-
ological bioenergetics of this tissue. Carnitine de)ciency
greatly a+ects skeletal muscle function as found in presence
of primary and secondary de)ciencies. Primary carnitine
de)ciency (OMIM 212140), which a+ects between 1 : 37.000–
1 : 100.000 newborn individuals, is an autosomal recessive
disorder of fatty acid oxidation resulting from defective
carnitine transport caused by mutations in carnitine trans-
porter gene SLC22A5 [75] coding for OCTN2 transport
protein. (e disease, characterized by very low level of
free and total carnitine (free carnitine 1–5휇M and normal
20–55휇M), may have a predominant metabolic or cardiac
presentation. (e metabolic presentation usually before 2
years of age is characterized by frequent gastrointestinal
and respiratory infections, lethargia, hepatomegaly, hypoke-
totic hypoglycemia, hyperammonemia, and serum creatine
kinase elevation [76]. Later cardiomyopathy and hypoto-
nia dominate the medical case [77]. Secondary carnitine
de)ciency is commonly associated with hemodialysis. In
chronic renal insu3ciency, undialyzed patients total carni-
tine, free carnitine, and acylcarnitine accumulate in body
tissues due to reduced renal clearance [78, 79]. Besides,
following regular hemodialysis, a signi)cant creatine loss
arises as demonstrated by reduction of creatine content in
serum and skeletal muscle during the dialysis session [80]
which is not compensated by endogenous synthesis [79].
Considering that the dialysate carnitine content before and
a5er hemodialysis is far below that of control subjects and
that the loss of carnitine into the dialysate greatly exceeds
that into urine, the net loss of carnitine is mostly attributed
to dialysis procedures [81, 82]. Indeed also the carnitine
cofactors and precursors, vitamin B6, niacin, vitamin C,
lysine, and methionine, may be lost throughout the dialysis
procedures [83]. Considering the role of carnitine in the cell,
bioenergetics, dyslipidemia, muscle fatigue, cardiomyopathy,
and anemia have been considered potential targets for L-
carnitine supplementation in several trials conducted in a
large cohort of hemodialyzed patients [83]. Meta-analysis of
the literature does not allow to draw consensus on whether
carnitine supplementation can improve the patient’s health
status. In particular, although initial systematic reviews of
published literature on the topic put forward a promising
e+ect on management of anemia and failed to demonstrate
a signi)cant e3cacy in controlling dyslipidemia [83], a
recent meta-analysis involving more than 1700 participants
failed to con)rm the previous )ndings regarding the e+ects
of L-carnitine on hemoglobin but showed that L-carnitine
signi)cantly decreases serum low-density lipoprotein (LDL)
and C-reactive protein (CRP). In this study the extent of
LDL decrease did not appear clinically relevant, whereas a
signi)cant and clinically relevant decrease of CRP serum
content was observed [84]. Importantly, these e+ects were
not con)rmed in another meta-analysis of randomized con-
trolled trials, which failed to demonstrate any improvement
of in,ammation, oxidative stress, nutrition, anemia, dys-
lipidemia, hyperparathyroidism status, or quality of life in
hemodialyzed patients [85]. Uncertainties also regard the
e+ect of L-carnitine administration on skeletal muscle func-
tion of hemodialyzed patients. Long-term administration (12
months) of L-carnitine (2 g/day) to hemodialyzed patients
resulted in increased serum and muscle carnitine levels, and
selective type 1 )ber hypertrophy [86] and similar results
have been obtained in uremic patients following 24 weeks
administration of the same dose [87] but the functional
signi)cance of such changes remains to be elucidated. Taken
together, available inconclusive results put forward that high-
quality and long-term randomized trials are still required to
fully elucidate the clinical value of L-carnitine administration
in these patients.
Other clinically relevant conditions may determine sec-
ondary carnitine de)ciency, that is, intestinal resection,
severe infections, liver disease, and cancer [88] where a
negative impact on skeletal muscle is demonstrated by the
appearance of pathological manifestations, including )bers
accumulation of neutral lipids, structural damages, and sub-
sarcolemmal accumulation of large aggregates of mitochon-
dria. (erefore, carnitine supplementation may represent a
useful tool for the management of muscle deterioration and
the appearance of fatigue in presence of carnitine loss.
Carnitine de)ciency is not the only condition that allows
to focus on its central role in muscle energy disposal and
handling. Carnitine availability may be the limiting factor
for fatty acid oxidation and/or the removal of acyl-CoAs
at rest and during low intensity exercise [89], and an
increase in skeletal muscle total carnitine content would
be expected to increase fatty acid oxidation and decrease
pyruvate dehydrogenase complex activation and glycogen use
during such exercise tasks. On the other side, during high
intensity exercise, carnitine shi5s towards acetylcarnitine
formation, thus maintaining the pyruvate dehydrogenase
complex and and tricarboxylic acid ,ux [90]. In accordance
with a dual role of carnitine in skeletal muscle energetics,
bene)cial e+ect of L-carnitine supplementation has been
observed at low intensity exercise where its availability
increases the rate of oxidation of intramuscular fatty acids and
triacylglycerols, thus postponing the appearance of fatigue
[91, 92]. Furthermore at high intensity exercise its availability
may lead to better matching of glycolytic and mitochondrial
,ux, thus reducing ATP formation by anaerobic mechanisms
[90, 93–97]. Importantly, some studies failed to observe
such e+ects [98–104], and inconsistencies may be laid on
the relevance of dietary means to carnitine retention a5er
supplementation, being favored by carbohydrates coingestion
through increased insulin level [90].
One of the most promising areas of research on L-
carnitine supplementation regards its potential role in ame-
liorating and accelerating recovery from exercise-induced
muscle injury. It has been found that supplemental carnitine
is e+ective in attenuating signs of tissue damage (muscle
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soreness and serum CK elevation) induced by lengthening
or intense contractions [105–108] also in sarcopenic muscle
[109]. (e observed bene)ts of L-carnitine supplementa-
tion in preventing load-induced muscle injury have been
attributed to its known role as antioxidant. In skeletal muscle,
reactive oxygen species (ROS) and nitrogen species are
physiologically synthesized at low levels and are required
for normal force production [110]. When ROS production
overtakes tissue antioxidant capacity, oxidative stress acti-
vates pathophysiologic signaling leading to proteolysis and
apoptosis within the myo)bers. (is sequence of events is
considered as a major cause of sarcolemmal damage and
leakage of cytosolic proteins as CK into the circulation
and the origin of reduced muscle strength capacity that
contributes to fatigue [111–113]. In exercise-induced muscle
damage L-carnitine supplementation has been found to
reduce postexercise serumCK [105, 106] andmyoglobin con-
centrations [106], suggesting a quicker muscle recovery from
damage. Further evidence demonstrated that L-carnitine has
an e+ective free-radicals scavenging activity at least in vitro
[114]. In contrast inconclusive results have been obtained
in vivo at least in humans on the e+ects of L-carnitine on
xanthine oxidase, a marker of metabolic stress that, in pres-
ence of high glycolytic rates, mediates the oxidation of AMP
to hypoxanthine [115]. Accumulation of xanthine oxidase
is the consequence of the activation of calcium-dependent
proteases, which cleave a portion of xanthine dehydrogenase
and convert it into xanthine oxidase.(is response appears to
be attenuated by L-carnitine supplementation which reduces
intracellular hypoxanthine and xanthine oxidase following
resistance exercise bouts [109] whereas other experimental
investigations failed to demonstrate such e+ect [116, 117].
Anothermechanism, bywhich high intensitymuscle con-
tractionsmay exert toxic e+ect on skeletal muscle, is transient
hypoxia. Under hypoxia, an increased concentration of blood
ammonia and a lower concentration of free carnitine have
been found [118, 119]. In this condition supplementation with
L-carnitine may prevent ammonia formation through its
antioxidant activity. Besides exercise, L-carnitine is known
to protect against muscle mitochondrial dysfunctions associ-
atedwith oxidative stress caused by a series of conditions such
as aging, ischemia reperfusion, in,ammation, degenerative
diseases, carcinogenesis, and drug toxicity, in vivo or in vitro
[120–134]. For instance, studies suggest that cancer cachexia,
which includes anorexia, weight loss, muscle loss, skeletal
muscle atrophy, anemia, and alterations in carbohydrate,
lipid, and protein metabolism [135], is associated with a
decrease in intracellular glutathione concentration in the
muscle [136–138], and L-carnitine supplementation increases
the tumor-induced decrease in muscular glutamate and glu-
tathione levels at least in animal models [136]. Gramignano
et al. [139], studying the e3cacy of L-carnitine supplemen-
tation (6 g/day for 4 weeks) in a population of advanced
cancer patients, found a decreased ROS and increased glu-
tathione peroxidase levels. Promising antioxidant activities
have been also found following supplementation in patients
with nonalcoholic steatohepatitis [140], renal disease [141],
and phenylketonuria [142], as well as in several experimental
models of oxidative stress [143–146]. Interestingly, recent
evidence suggests that carnitine supplementation may also
directly act as radical scavenger, thus contributing to pro-
tection against statin-induced oxidative muscle damage [146,
147].
In summary, considering its importance inmuscle bioen-
ergetics and its antioxidant potential, L-carnitine supplemen-
tation may be considered an aid in presence of carnitine
de)ciency and in skeletal muscle diseases in which oxidative
stress and altered fatty acid oxidation mostly contribute to
pathophysiology. Despite this potential, further research is
needed to conclusively elucidate the mechanisms underlying
its protective e+ects and to establish whether they may also
arise in presence of muscle diseases of di+erent origin.
4. 휔3 Long Chain Polyunsaturated Fatty Acids
(휔3 LC-PUFAs)
4.1. ,e Nutritional Biochemistry of 휔3 LC-PUFAs. 휔3
PUFAsare among the most studied nutrients which show
healthy properties [148]. 훼-Linolenic acid (ALA—C18:3, 휔3,
Figure 3), which is not synthesized in the human body and
therefore must be consumed with the diet, is the precursor of
the twomost important bioactive long chain polyunsaturated
fatty acids (휔3 LC-PUFA, Figure 3): eicosapentaenoic acid
(EPA—C20:5 휔3) and docosahexaenoic acid (DHA—C22:6휔3). In the endoplasmic reticulum, ALA is converted in EPA
and DHA through the development of enzymatic elongation
and desaturation reactions, in which Δ-6 desaturase and
elongase andΔ-5 desaturase enzymes are involved. In peroxi-
somes, these reactions are followed by훽-oxidation to produce
DHA. 휔3 LC-PUFAs are considered “conditionally essential”
because occasionally they are not synthesized in su3cient
amounts to meet human needs. (is condition occurs when
the dietary intake of ALA is too low in comparison with
linoleic acid (LA, C18:2-휔6) and the ratio 휔6/휔3 is higher
than 5/1. (us, due to the competition of ALA and LA for
the same Δ-6 desaturase enzyme, which is shared in the
two metabolic pathways, the production of LC-PUFAs shi5s
towards the synthesis of 휔6 fatty acids. It is therefore evident
that the intake of both ALA and EPA and DHA should be
encouraged.(e most important sources of 휔3 LC-PUFAs in
human nutrition are fatty )sh, such as sardines, salmon, and
tuna, as well as walnuts, and ,axseed, and canola oils.
Once produced from ALA, EPA and DHA, in turn, are
precursors of eicosanoids thatmediate the anti-in,ammatory
e+ects that underlie the bene)cial e+ects ascribed to 휔3 LC-
PUFAs in numerous physiological and pathological states.
In particular, increasing evidence suggests that 휔3 PUFAs
improve blood lipid levels (inducing a decrease of triglyc-
eride levels and an increase of HDL cholesterol), reduce
arrhythmias and risk of stroke, and help to prevent and
treat atherosclerosis [149, 150]. Moreover, 휔3 PUFAs were
shown to have chemopreventive properties against various
types of cancer, including colon and breast cancer [151,
152]. Some recent studies suggest that 휔3 PUFAs intake is
associated with reduced depressive symptoms, particularly in
females, potentiating the e+ects of antidepressants, and helps
to reduce mood swings [153, 154]. (e protective e+ect of
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Figure 3: Chemical structure of 훼-linolenic acid (ALA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA).
DHA in amyloid-훽 peptide-infused rats was associated with
increased membrane ,uidity which also provided oxidative
stress resistance in hippocampal cells [155, 156]. In vivo, 휔3
LC-PUFAs increased membrane ,uidity in rat hippocampus
and improved memory formation, whereas their reduction
exerted opposite e+ects [157, 158]. Preclinical studies sup-
ported the idea that DHA maintained membrane ,uid-
ity, improved synaptic and neurotransmitter functioning,
enhanced learning andmemory performances, and displayed
neuroprotective properties [159]. Moreover, DHA decreased
the amount of vascular amyloid-훽 peptide (A훽) deposition
and reduced A훽 burden [160, 161].
Interesting avenues of research also regard the treatment
of chronic in,ammatory diseases of the bone as rheumatoid
arthritis [162, 163]. Importantly, 휔3 PUFAs have shown
bene)cial e+ects on bone health in animal studies [164, 165]
but current research suggests only a modest increase in bone
turnover in humans [166].
4.2. ,e E-ects of 휔3 PUFA Supplementation on Muscle
Diseases. Research on the role of PUFAs inmuscle health and
functionality is still incomplete and deserves future in-depth
analysis. Promising observations suggest an important role
of dietary 휔3 PUFA supplementation on protein synthesis
and in,ammation and its potential e3cacy in lean bodymass
sparing. Initial evidence suggests that )sh-oil-derived 휔3
PUFAsmight be useful in preventing and treating sarcopenia
of ageing. (is e+ect appears mediated by increased insulin
levels and amino acid mediated activation (i.e. phosphoryla-
tion) of signaling proteins of the mTOR/p70S6K1 pathway,
as demonstrated in animal models (i.e. growing steers and
burned guinea pigs) [167, 168]. In 2011, Smith et al. in two
randomized studies [169–171] demonstrated the e+ect of 휔3
PUFA supplementation (1.86 g EPA and 1.50 g DHA for 8
weeks) on muscle protein metabolism in young/middle-aged
(mean age: 37 years) and elderly subjects (mean age: 65
years) of both sexes. Importantly, in all individuals, 휔3 PUFA
supplementation, although not exerting any e+ect on the
basal rate of protein synthesis, determined the augmentation
of the hyperaminoacidemia-hyperinsulinemia-induced rate.
(is change was accompanied by increased phosphoryla-
tion of mTOR in serine 2448 and downstream p70S6K
in threonine 389, whereas no change in the level of Akt
(the main e+ector of insulin activation upstream mTOR)
phosphorylation was observed. Interestingly, the e+ect on
protein synthesis was not associated with lower plasma
concentration of in,ammatory markers and triglycerides,
thus suggesting that the anabolic e+ect of PUFAs may arise
independently of their known anti-in,ammatory e+ect [169].
Furthermore the observed anabolic e+ect did not produce
signi)cant amelioration of glycemic control through changes
in skeletal muscle insulin sensitivity, which is generally, but
not universally [172–175], accepted to be improved by 휔3
PUFA supplementation. In fact, Liu et al.[172] showed that
in rats fed with a high-휔3 fatty acid diet there is an increase
of insulin binding to sarcolemma due to changes of the
fatty acyl composition of phospholipids surrounding the
insulin receptor. (e authors suggested that this might be
the mechanism by which dietary fatty acids modify insulin
action. More recently, in rats fed with a high-saturated fat
diet, Holness et al. [173] reported that hyperinsulinemia
can be rapidly reversed via the dietary provision of small
amounts of휔3 PUFA. However, the saving of insulin induced
by 휔3 PUFA supplementation occurs in the absence of an
acute improvement of insulin sensitivity. (ese results are
not surprising as the published available information on the
e+ects of PUFA supplementation on insulin sensitivity in
humans is inconsistent and o5en contradictory [176–180].
Considering that maintenance of muscle mass is a fun-
damental determinant of its capacity to generate force, of
interest is the potential correlation between PUFAs consump-
tion and muscle strength in the elderly. So far, inconclusive
results are available [180, 181]. In particular, in 2009, a cross-
sectional study found no correlation between total 휔3 or휔6 PUFA intakes and muscle strength in aged Americans
[180], whereas, in 2013, the Tokyo Oldest Old Survey on Total
Health showed that higher consumption of EPA and DHA
is signi)cantly associated with higher functional mobility
in men. (is e+ect was not observed in women [181]. (e
only available randomized double blind pilot study analyzed
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the e+ects of 2 )sh oil (1.2 g EPA andDHA) or 2 placebo (olive
oil) capsules per day for 6 months in 126 postmenopausal
women [182]. Fatty acid levels, frailty assessment, hand grip
strength, 8-foot walk, body composition, and in,ammatory
biomarkers were taken at baseline and a5er 6 months of
supplementation. Fish oil supplementation resulted in higher
red blood cell DHA, compared to baseline and placebo,
and improvement in walking speed compared to placebo.
In this work a linear regression model including age, vita-
min intake, osteoarthritis, frailty phenotype, and tumor
necrosis factor alpha (TNF-훼) explained that the change in
DHA/arachidonic ratio, TNF-훼, and selenium intake had
the major contribution to the observed change in walking
speed [182]. Importantly, new avenues of research highlight
that a fundamental booster of the functional e+ects of )sh
oil supplementation is physical exercise and, in particular,
strength training. In 2012, Rodacki and coworkers [183], in
a randomized study enrolling elderly women, demonstrated
that the use of )sh oil for 90 days in addition to strength
training (3 times/week, for 12weeks, 36 training sessions) was
associated with an additional increase of peak torque and rate
of torque development, which, de facto, de)nes an improve-
ment in whole body functional capacity as demonstrated by
higher chair-rising performance. Notably, the mechanisms
underlying these changes remain obscure and the potential
role of )sh oil in changing the ,uidity of the muscle )bers
membrane and acetylcholine sensitivity should be taken into
consideration [183].
(erefore, available data suggest a potential role of 휔3
PUFA supplementation in muscle anabolism and function-
ality at least in presence of sarcopenia of ageing. Future
studies are needed to investigate whether these e+ects might
be quantitatively relevant in other myopathic conditions.
Another fundamental mechanism to be taken into con-
sideration when analyzing the potential bene)t of 휔3 PUFA
supplementation in healthy and diseased skeletal muscle is
the largely demonstrated inhibitory e+ect on in,ammation
[184]. 휔3 PUFAs serve as precursors to prostaglandins such
as prostaglandin E3, which are powerful hormone-like sub-
stances that reduce in,ammation [185], and inhibit arachi-
donic acid, derived 2-series prostaglandins, and the 4-series
leucotrienes, which are known tomodulate the production of
proin,ammatory and immunoregulatory cytokines [186]. In
vivo and ex vivo animal studies have indicated that휔3 PUFAs
reduce the production of TNF-훼, IL-1, IL-2, and IL-6 [187–
189]. In humans contradictory observations still exist, since
some lines of evidence suggest that supplementation of the
diet with )sh oils results in a reduced production of IL-1, IL-
6, TNF-훼, and IL-2 [190], and an alteration of gene expression
pro)les to a more antiin,ammatory and antiatherogenic
status in peripheral blood mononuclear cells in vitro [191];
whereas, in vivo, dietary supplementation with PUFAs pro-
duced either no change [192] or amelioration of hallmarks of
muscle damage (i.e., soreness and creatine kinase levels) and
in,ammatory mediators (i.e. IL6), following physiological
proin,ammatory events such as strenuous exercise or eccen-
tric contractions in unaccustomed individuals [193, 194].
Finally, the change in lipid composition of the membranes
(i.e. the sarcolemmal membranes) might be considered
an additional, not enough explored, e+ect of PUFA supple-
mentation on skeletal muscle. It is well known that changes
in lipid composition may in,uence membrane function by
regulating protein and lipid membrane homeostasis [195–
197], and PUFAs either as constituents of membrane phos-
pholipids or free molecules contribute to membrane chemo-
physical features (i.e., membrane organization, ion perme-
ability, elasticity, and microdomain formation). In particular,
it has been shown that 휔3 PUFA supplementation decreases
membrane thickness [198, 199], modulates protonmembrane
permeability and lea,et thickness enhancing fatty acid ,ip-
,op rate, and increases bilayer propensity to be in a liquid-
disordered phase [196]. (e anti-in,ammatory potential of휔3 PUFAs together with their e3cacy inmodulatingmyocyte
membrane composition and conformation [197, 200–202]
was the rational basis for recent preliminary attempts aiming
at identifying new strategies for the treatment of cancer
cachexia andmuscular dystrophieswhere in,ammation plays
a major role in the pathogenesis of muscle wasting [203].
Unfortunately, only few and contradictory studies are
available. Inconclusive results are available on whether the
anti-in,ammatory e+ects of PUFAs can counteract the action
of proin,ammatory cytokines involved in the pathogenesis
of cancer cachexia [203], and the available randomized
controlled clinical trials could not safely demonstrate pos-
itive e+ects of supplementation on muscle wasting [204].
Few and contradictory results have also been obtained in
muscular dystrophies. In particular, Fiaccavento et al. have
demonstrated that supplementation of dystrophic UM-X7.1
hamsters, carrying a phenotype similar to limb girdle mus-
cular dystrophy 2F (LGMD2F) with ALA, precludes myocyte
and muscular tissue damage and modulates cells prolifera-
tion promoting myogenic di+erentiation. Two major factors
concurred to determine such e+ects including the modula-
tion of the lipid membrane composition and con)guration
which appears altered in such model [205] associated with
the preservation of the expression and location of key-role
signaling proteins (i.e. 훽-catenin, caveolin-3, sarcoglycan,
and dystroglycan) and the slowing down of the myocyte
degeneration/regeneration cycling rate associated with the
enhancement of the myogenic di+erentiation [206]. Further,
initial observations suggest that 휔3 PUFA supplementation
with )sh oil or EPA decreases muscle degeneration and
in,ammation in mdx mouse model mirrored by reduced
functional impairment evaluated by grip strength tests [207,
208]. On the contrary, by using a highly controlled diet
design, Henderson et al. [209] have recently put forward
a detrimental e+ect of a high intake of 휔3 PUFA, unlike
high MUFA, in the same animal model as demonstrated by
higher serum CK activity and no changes in skeletal muscle
histopathology and in,ammatory markers (p65) [209]. Con-
gruent with the latter observations, Galvao and coworkers
[210] have recently demonstrated that high 휔3-PUPA diet
enriched with 훼-linoleic and 훼-linolenic acid, unlike high
long chain saturated fatty acids diet, promotes a negative
e+ect on lifespan in the same animal model with genetic
cardiomyopathy. Importantly the harmful e+ect on survival
of the high PUFA diet appeared to be associated with highly
signi)cant increase in plasma free fatty acids whose elevation
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is correlated with higher risk of ventricular arrhythmias and
is considered a strong predictor of sudden cardiac death
[211, 212].
(erefore, considering the available research studies, it is
not currently possible to draw safe conclusions on the role of휔3 PUFA in muscle diseases and further studies are )rst
needed to elucidate whether supplementation may be harm-
ful in certain myopathic conditions.
5. Conclusion
Myopathies are chronic degenerative diseases that induce
the deterioration of the structure and function of skeletal
muscle characterized by progressive strength loss, muscle
fatigue, pain, or tenderness, cramps, sti+ness, and tightness.
So far, curative therapies are not available and the goals of
treatment are now )nalized to delay the onset of the disease
and to relieve symptoms. (erefore, myopathic patients are
submitted to interventions, such as rehabilitation, ventilatory
assistance, and nutritional approach, which have the main
purposes of improving the quality of life and slowing the
progression of the disease. In particular an adequate diet,
which has su3cient caloric content and balanced nutritional
composition, and speci)c nutritional supplements can help
myopathic patients. (e presented review of the literature
suggests that creatine, L-carnitine, and 휔3-PUFA supple-
mentation may have the potential to exert bene)cial e+ects
in selected myopathies. Nevertheless, to date, experimental
evidence of short-term and long-term e+ects of supplemen-
tation in myopathies with heterogeneous physiopathology is
missing. Indeed, the evidence of potential harmful e+ects in
short-term settings (휔3 PUFA in animal models of dystro-
phy and cardiomyopathy and creatine in McArdle disease)
and the lack of studies on the potential harmful e+ects of
prolonged supplementations strongly highlight that further
rigorous studies are required before these supplementations
could be recommended as a treatment in selected muscle
diseases.
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